Recent Public Biotech Acquisitions
This article was originally published in Start Up
Executive Summary
While biotechs selling services to Big Pharma appear to avoid the risks of product development, profitability has nevertheless proved much more elusive to these companies than originally expected, as demonstrated by their acquisition prices.